EnteroBiotix appoints former GSK Chief Medical Officer to board

pharmafile.com | November 3, 2026 | Appointment | |  Cardiology, EnteroBiotix, GSK, Obesity, Pharmacy, appointments, approvals 

EnteroBiotix has appointed Dr Murray Stewart, former Chief Medical Officer at GSK and Rhythm Pharmaceuticals, to its Board of Directors.

Stewart has also served as Head of Research and Development at Novelion Therapeutics. During his time at Rhythm, he helped secure the first US and European approvals of setmelanotide (IMCIVREE) for certain rare genetic obesity disorders.

At GSK, he held senior clinical and patient safety responsibilities across the company’s pharmaceutical, vaccine and consumer healthcare businesses, having previously worked in cardiovascular and metabolic medicine.

EnteroBiotix is developing oral, full-spectrum microbiome therapeutics. Its lead programme, EBX-102-02, is being evaluated in the phase 2b RISE study in irritable bowel syndrome with constipation (IBS-C). The randomised, double-blind, placebo-controlled trial is expected to enrol around 300 patients, building on findings from the company’s phase 2a TrIuMPH study.